BNP Paribas Asset Management
RXRX icon

BNP Paribas Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History

BNP Paribas Asset Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.43M Sell
790,971
-8,107
-1% -$31.3K ﹤0.01% 1037
2025
Q4 		$3.27M Buy
799,078
+796,125
+26,960% +$3.94M ﹤0.01% 944
2025
Q3 		$14K Buy
2,953
+334
+13% +$1.75K ﹤0.01% 1532
2025
Q2 		$13K Buy
+2,619
New +$12.9K ﹤0.01% 1684

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Asset Management's RXRX Position: Q1 2026 in Review

BNP Paribas Asset Management reduced its Recursion Pharmaceuticals (RXRX) stake by 1% in Q1 2026, selling an estimated $31.3K and leaving 790,971 shares worth $2.43M. The position accounts for ﹤0.01% of the portfolio, ranked #1037.

BNP Paribas Asset Management first reported a position in RXRX in Q2 2025 and has held it in 4 quarters since. The position peaked at $3.27M in Q4 2025. 335 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • BNP Paribas Asset Management held 790,971 shares of Recursion Pharmaceuticals worth $2.43M as of Q1 2026.
  • BNP Paribas Asset Management sold 8,107 Recursion Pharmaceuticals shares in Q1 2026, an estimated $31.3K.
  • Recursion Pharmaceuticals made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q1 2026, its #1037 holding.
  • BNP Paribas Asset Management first reported a position in Recursion Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • BNP Paribas Asset Management's Recursion Pharmaceuticals position peaked at $3.27M in Q4 2025.
  • 335 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on BNP Paribas Asset Management's 13F filing for Q1 2026, filed 14 May 2026.